258P Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)

Autor: Muiño, C. Bueno, Diaz-Guardamino, I. Echavarria, Alvarez, E., Gilarranz, Y. Jerez, Lopez, B. Herrero, Del Monte, M., Massarrah, T., Cebollero, M., Nevado, M., Barrio, P.D.L.M. de la Morena, Ayala de la Pena, F., Saenz, J.Á. García, Anton, F. Moreno, Rodriguez, A., Verduguez, T. Quintanar, Gimenez, D. Malon, Garcia, A.I. Ballesteros, Bañón, D., Lopez-Tarruella Cobo, S., Jimenez, M. Martin
Zdroj: In Annals of Oncology September 2024 35 Supplement 2:S323-S323
Databáze: ScienceDirect